Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Stryker Corporation (SYK)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$335.08-1.35%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
16.71 → 16.33 EPS · FY ending Dec 31, 2027 · 16 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 16; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SYK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain adjusted EPS near $15 in 2026 | A primary condition in Stryker Corporation's published investment case. The stated target is $14.90 to $15.10 EPS. | Intact | Adjusted EPS falls below $14.90 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
SYK is a medical-device business with a growth-and-margin improvement thesis, supported by a favorable sector backdrop. The long-term thesis is intact, though the latest results put management’s delivery against its prior outlook behind plan.
The valuation evidence is mixed: SYK is described as cheap versus peers, while also carrying a substantial premium to peers. The expectations gap is slightly negative, and the snapshot labels expectations as justified rather than fragile.
Near term, organic sales and adjusted earnings are still growing, and adjusted operating margin improved in Q3. But management cut full-year sales and earnings guidance after saying Q3 fell short of expectations, while the recent earnings miss and weaker momentum raise execution concerns.
The multi-year thesis depends on renewed delivery on organic sales growth and adjusted earnings growth while margin gains continue. Near-term risks include another guidance cut and weaker jobs data; continued earnings strength and higher guidance from sector peers would support the sector backdrop.
Over the next 1 to 3 years, SYK retains a credible growth and margin thesis, but recent guidance reductions and missed expectations make execution the key test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Stryker Corporation's published investment case. The stated target is No material operational disruption from cybersecurity issues. |
| Intact |
| Material operational disruption or new cybersecurity incidents occur |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain organic net sales growth near 8.75% in 2026 | A primary condition in Stryker Corporation's published investment case. The stated target is 8.0% to 9.5% YoY revenue growth. | Under Pressure | YoY revenue growth falls below 8.0% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$16.72 → $16.33 · observed estimates
$29.59B → $28.74B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $16.72 | $29,588,964,350 | 26 / 26 |
| 2026-07-25 | $16.72 | $29,588,964,350 | 26 / 26 |
| 2026-07-26 | $16.72 | $29,601,278,981 | 15 / 20 |
| 2026-07-27 | $16.72 | $29,588,887,430 | 26 / 26 |
| 2026-07-28 | $16.72 | $29,601,278,981 | 15 / 20 |
| 2026-07-29 | $16.73 | $29,602,275,082 | 16 / 20 |
| 2026-07-30 | $16.73 | $29,590,298,170 | 27 / 27 |
| 2026-07-31 | $16.75 | $29,617,256,701 | 16 / 20 |
| 2026-08-01 | $16.75 | $29,617,256,701 | 16 / 20 |
| 2026-08-02 | $16.76 | $29,599,464,520 | 27 / 27 |
| 2026-08-03 | $16.76 | $29,599,464,520 | 27 / 27 |
| 2026-08-04 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-05 | $16.76 | $29,678,514,690 | 27 / 27 |
| 2026-08-06 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-08 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-09 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-10 | $16.76 | $29,681,085,670 | 27 / 27 |
| 2026-08-12 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-13 | $16.76 | $29,681,085,670 | 27 / 27 |
| 2026-08-14 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-15 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-16 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-17 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-18 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-19 | $16.77 | $29,611,673,523 | 15 / 20 |
| 2026-08-20 | $16.76 | $29,697,631,394 | 16 / 20 |
| 2026-08-21 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-22 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-23 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-24 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-25 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-26 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-27 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-28 | $16.76 | $29,697,631,502 | 16 / 20 |
| 2026-08-29 | $16.76 | $29,697,642,781 | 16 / 20 |
| 2026-08-30 | $16.76 | $29,697,642,781 | 16 / 20 |
| 2026-08-31 | $16.76 | $29,697,642,781 | 16 / 20 |
| 2026-09-01 | $16.76 | $29,697,642,781 | 16 / 20 |
| 2026-09-02 | $16.76 | $29,697,642,781 | 16 / 20 |
| 2026-09-03 | $16.76 | $29,697,642,781 | 16 / 20 |
| 2026-09-04 | $16.76 | $29,697,642,781 | 15 / 20 |
| 2026-09-05 | $16.76 | $29,697,642,781 | 15 / 20 |
| 2026-09-06 | $16.76 | $29,697,642,781 | 15 / 20 |
| 2026-09-07 | $16.76 | $29,697,642,781 | 15 / 20 |
| 2026-09-08 | $16.76 | $29,697,642,781 | 15 / 20 |
| 2026-09-09 | $16.75 | $29,679,001,636 | 15 / 20 |
| 2026-09-10 | $16.75 | $29,674,481,570 | 15 / 20 |
| 2026-09-11 | $16.75 | $29,662,201,805 | 15 / 20 |
| 2026-09-12 | $16.75 | $29,662,201,805 | 15 / 20 |
| 2026-09-13 | $16.75 | $29,662,201,805 | 16 / 20 |
| 2026-09-14 | $16.75 | $29,662,201,805 | 16 / 20 |
| 2026-09-15 | $16.74 | $29,659,190,977 | 16 / 20 |
| 2026-09-16 | $16.74 | $29,659,230,977 | 16 / 20 |
| 2026-09-17 | $16.74 | $29,645,112,157 | 16 / 20 |
| 2026-09-18 | $16.74 | $29,645,112,157 | 16 / 20 |
| 2026-09-19 | $16.74 | $29,645,112,157 | 16 / 20 |
| 2026-09-20 | $16.74 | $29,644,592,157 | 16 / 20 |
| 2026-09-21 | $16.74 | $29,644,592,157 | 16 / 20 |
| 2026-09-22 | $16.73 | $29,632,232,157 | 16 / 20 |
| 2026-09-23 | $16.73 | $29,623,990,968 | 16 / 20 |
| 2026-09-24 | $16.73 | $29,623,990,968 | 16 / 20 |
| 2026-09-25 | $16.73 | $29,623,990,968 | 16 / 20 |
| 2026-09-26 | $16.73 | $29,615,466,968 | 16 / 20 |
| 2026-09-27 | $16.73 | $29,615,466,968 | 16 / 20 |
| 2026-09-28 | $16.73 | $29,615,466,968 | 16 / 20 |
| 2026-09-29 | $16.73 | $29,615,466,968 | 16 / 20 |
| 2026-09-30 | $16.73 | $29,615,466,968 | 16 / 20 |
| 2026-10-01 | $16.72 | $29,610,266,968 | 16 / 20 |
| 2026-10-02 | $16.72 | $29,608,414,968 | 16 / 20 |
| 2026-10-03 | $16.72 | $29,608,414,968 | 16 / 20 |
| 2026-10-04 | $16.72 | $29,608,414,968 | 16 / 20 |
| 2026-10-05 | $16.72 | $29,608,414,968 | 16 / 20 |
| 2026-10-06 | $16.71 | $29,592,894,968 | 16 / 20 |
| 2026-10-07 | $16.71 | $29,565,674,676 | 16 / 20 |
| 2026-10-08 | $16.70 | $29,559,594,676 | 16 / 20 |
| 2026-10-09 | $16.70 | $29,559,600,508 | 16 / 20 |
| 2026-10-10 | $16.70 | $29,559,600,508 | 16 / 20 |
| 2026-10-11 | $16.70 | $29,551,280,508 | 16 / 20 |
| 2026-10-12 | $16.70 | $29,551,280,508 | 16 / 20 |
| 2026-10-13 | $16.69 | $29,535,913,850 | 16 / 20 |
| 2026-10-14 | $16.70 | $29,527,995,655 | 16 / 20 |
| 2026-10-15 | $16.69 | $29,535,913,850 | 16 / 20 |
| 2026-10-16 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-17 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-18 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-19 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-20 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-21 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-22 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-23 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-24 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-25 | $16.68 | $29,531,253,748 | 16 / 20 |
| 2026-10-26 | $16.68 | $29,531,253,748 | 15 / 20 |
| 2026-10-27 | $16.68 | $29,531,253,748 | 15 / 20 |
| 2026-10-28 | $16.68 | $29,531,253,617 | 15 / 20 |
| 2026-10-29 | $16.68 | $29,531,253,617 | 16 / 20 |
| 2026-10-30 | $16.67 | $29,512,571,517 | 16 / 20 |
| 2026-10-31 | $16.36 | $28,896,137,644 | 16 / 20 |
| 2026-11-01 | $16.36 | $28,896,127,952 | 16 / 20 |
| 2026-11-02 | $16.36 | $28,896,127,952 | 16 / 20 |
| 2026-11-03 | $16.34 | $28,762,303,242 | 17 / 20 |
| 2026-11-04 | $16.33 | $28,738,211,810 | 16 / 20 |
| 2026-11-05 | $16.33 | $28,738,211,810 | 16 / 20 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 23 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 14 recorded
0 raises · 5 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.